메뉴 건너뛰기




Volumn 108, Issue 1, 2008, Pages 90-94

Randomized trial of pegylated liposomal doxorubicin (PLD) plus carboplatin versus carboplatin in platinum-sensitive (PS) patients with recurrent epithelial ovarian or peritoneal carcinoma after failure of initial platinum-based chemotherapy (Southwest Oncology Group Protocol S0200)

Author keywords

Carboplatin; Ovarian cancer; Pegylated liposomal doxorubicin; Platinum sensitive

Indexed keywords

CARBOPLATIN; DOCETAXEL; DOXORUBICIN; PACLITAXEL; PLATINUM DERIVATIVE;

EID: 37349126263     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2007.08.075     Document Type: Article
Times cited : (115)

References (8)
  • 1
    • 0037862963 scopus 로고    scopus 로고
    • Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial
    • Parmar M.K., Ledermann J.A., Colombo N., du Bois A., Delaloye J.F., Kristensen G.B., et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 361 (2003) 2099-2106
    • (2003) Lancet , vol.361 , pp. 2099-2106
    • Parmar, M.K.1    Ledermann, J.A.2    Colombo, N.3    du Bois, A.4    Delaloye, J.F.5    Kristensen, G.B.6
  • 2
    • 33750588670 scopus 로고    scopus 로고
    • Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC CGC
    • Pfisterer J., Plante M., Vergote I., du Bois A., Hirte H., Lacave A.J., et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC CGC. J Clin Oncol 24 (2006) 4699-4707
    • (2006) J Clin Oncol , vol.24 , pp. 4699-4707
    • Pfisterer, J.1    Plante, M.2    Vergote, I.3    du Bois, A.4    Hirte, H.5    Lacave, A.J.6
  • 3
    • 0033850066 scopus 로고    scopus 로고
    • Phase II study of liposomal doxorubicin in platinum- and paclitaxel refractory epithelial ovarian cancer
    • Gordon A.N., Granai C.O., Rose P.G., Hainsworth J., Lopez A., Weissman C., et al. Phase II study of liposomal doxorubicin in platinum- and paclitaxel refractory epithelial ovarian cancer. J Clin Oncol 18 (2000) 3093-3100
    • (2000) J Clin Oncol , vol.18 , pp. 3093-3100
    • Gordon, A.N.1    Granai, C.O.2    Rose, P.G.3    Hainsworth, J.4    Lopez, A.5    Weissman, C.6
  • 4
    • 4644225190 scopus 로고    scopus 로고
    • Doxil Study 30-49 Investigators. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer
    • Gordon A.N., Tonda M., Sun S., and Rackoff W. Doxil Study 30-49 Investigators. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol 95 (2004) 1-8
    • (2004) Gynecol Oncol , vol.95 , pp. 1-8
    • Gordon, A.N.1    Tonda, M.2    Sun, S.3    Rackoff, W.4
  • 5
    • 33847304901 scopus 로고    scopus 로고
    • Second-line chemotherapy with pegylated liposomal doxorubicin and carboplatin is highly effective in patients with advanced ovarian cancer in late relapse: a GINECO phase II trial
    • Ferrero J.M., Weber B., Geay J.F., Lepille D., Orfeuvre H., Combe M., et al. Second-line chemotherapy with pegylated liposomal doxorubicin and carboplatin is highly effective in patients with advanced ovarian cancer in late relapse: a GINECO phase II trial. Ann Oncol 18 (2007) 263-268
    • (2007) Ann Oncol , vol.18 , pp. 263-268
    • Ferrero, J.M.1    Weber, B.2    Geay, J.F.3    Lepille, D.4    Orfeuvre, H.5    Combe, M.6
  • 7
    • 0035879099 scopus 로고    scopus 로고
    • Recurrent epithelial ovarian-carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan
    • Gordon A.N., Fleagle J.T., Guthrie D., Parkin D.E., Gore M.E., and Lacave A.J. Recurrent epithelial ovarian-carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 19 (2001) 3312-3322
    • (2001) J Clin Oncol , vol.19 , pp. 3312-3322
    • Gordon, A.N.1    Fleagle, J.T.2    Guthrie, D.3    Parkin, D.E.4    Gore, M.E.5    Lacave, A.J.6
  • 8
    • 33747881919 scopus 로고    scopus 로고
    • Gynecologic Cancer InterGroup. GOG 0182-ICON5: 5-arm phase III randomized trial of paclitaxel and carboplatin vs combinations with gemcitabine, PEG-liposomal doxorubicin, or topotecan in patients with advanced-stage epithelial ovarian or primary peritoneal carcinoma
    • Bookman M.A. Gynecologic Cancer InterGroup. GOG 0182-ICON5: 5-arm phase III randomized trial of paclitaxel and carboplatin vs combinations with gemcitabine, PEG-liposomal doxorubicin, or topotecan in patients with advanced-stage epithelial ovarian or primary peritoneal carcinoma. J Clin Oncol, ASCO Annual Meeting Proceedings vol. 18S (2006) 5002
    • (2006) J Clin Oncol, ASCO Annual Meeting Proceedings , vol.18 S , pp. 5002
    • Bookman, M.A.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.